US Patent

US10376470 — Oral tablet formulation consisting of fixed combination of rosuvastatin and ezetimibe for treatment of hyperlipidemia and cardiovascular diseases

Method of Use · Assigned to ALTHERA LIFE SCIENCES LLC · Expires 2033-05-01 · 7y remaining

Vulnerability score 62/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects an oral tablet formulation of a fixed combination of rosuvastatin and ezetimibe for treating hyperlipidemia and cardiovascular diseases.

USPTO Abstract

Solid dosage formulations containing a combination of rosuvastatin and ezetimibe, as well as methods of making such solid dosage forms and method of treating patients with fixed combination solid dosage forms of rosuvastatin and ezetimibe are provided here.

Drugs covered by this patent

Zetia (EZETIMIBE) · Merck & Co.

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3095`	—	Zetia
`U-3095`	—	Zetia
`U-3095`	—	Zetia
`U-3095`	—	Zetia

Patent Metadata

Patent number: US10376470
Jurisdiction: US
Classification: Method of Use
Expires: 2033-05-01
Drug substance claim: No
Drug product claim: Yes
Assignee: ALTHERA LIFE SCIENCES LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.